- Home
- RMTI vs CVKD Comparison
RMTI vs CVKD Comparison
Compare RMTI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- CVKD
- Stock Information
- Founded
- RMTI 1994
- CVKD 2022
- Country
- RMTI United States
- CVKD United States
- Employees
- RMTI N/A
- CVKD N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- RMTI Health Care
- CVKD Health Care
- Exchange
- RMTI Nasdaq
- CVKD Nasdaq
- Market Cap
- RMTI 32.5M
- CVKD 29.5M
- IPO Year
- RMTI 1998
- CVKD 2023
- Fundamental
- Price
- RMTI $1.29
- CVKD $13.00
- Analyst Decision
- RMTI Strong Buy
- CVKD Strong Buy
- Analyst Count
- RMTI 2
- CVKD 1
- Target Price
- RMTI $4.00
- CVKD $32.00
- AVG Volume (30 Days)
- RMTI 387.7K
- CVKD 35.0K
- Earning Date
- RMTI 08-07-2025
- CVKD 08-06-2025
- Dividend Yield
- RMTI N/A
- CVKD N/A
- EPS Growth
- RMTI N/A
- CVKD N/A
- EPS
- RMTI N/A
- CVKD N/A
- Revenue
- RMTI $97,727,000.00
- CVKD N/A
- Revenue This Year
- RMTI N/A
- CVKD N/A
- Revenue Next Year
- RMTI $11.16
- CVKD N/A
- P/E Ratio
- RMTI N/A
- CVKD N/A
- Revenue Growth
- RMTI 12.82
- CVKD N/A
- 52 Week Low
- RMTI $0.78
- CVKD $5.70
- 52 Week High
- RMTI $5.15
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- RMTI 74.79
- CVKD 49.98
- Support Level
- RMTI $0.80
- CVKD $11.00
- Resistance Level
- RMTI $0.87
- CVKD $13.56
- Average True Range (ATR)
- RMTI 0.08
- CVKD 1.15
- MACD
- RMTI 0.05
- CVKD 0.25
- Stochastic Oscillator
- RMTI 79.69
- CVKD 80.97
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.